

This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

POTENT *IN VITRO* ANTICANCER ACTIVITIES OF RING-EXPANDED ("FAT") NUCLEOSIDES CONTAINING THE IMIDAZO[4,5-*E*][1,3]DIAZEPINE RING SYSTEM

Juliana K. Gill^a; Lijuan Wang^a; Maria Bretner^a; Rachel Newman^b; Natasha Kyprianou^b; Ramachandra S. Hosmane^a

^a Laboratory for Drug Design and Synthesis, Department of Chemistry & Biochemistry, University of Maryland, Baltimore, Maryland, U.S.A. ^b Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, U.S.A.

Online publication date: 31 March 2001

To cite this Article Gill, Juliana K. , Wang, Lijuan , Bretner, Maria , Newman, Rachel , Kyprianou, Natasha and Hosmane, Ramachandra S.(2001) 'POTENT *IN VITRO* ANTICANCER ACTIVITIES OF RING-EXPANDED ("FAT") NUCLEOSIDES CONTAINING THE IMIDAZO[4,5-*E*][1,3]DIAZEPINE RING SYSTEM', Nucleosides, Nucleotides and Nucleic Acids, 20: 4, 1043 — 1045

To link to this Article: DOI: 10.1081/NCN-100002487

URL: <http://dx.doi.org/10.1081/NCN-100002487>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**POTENT *IN VITRO* ANTICANCER ACTIVITIES
OF RING-EXPANDED
("FAT") NUCLEOSIDES CONTAINING THE
IMIDAZO[4,5-*E*][1,3]DIAZEPINE RING SYSTEM**

**Juliana K. Gill,¹ Lijuan Wang,¹ Maria Bretner,¹
Rachel Newman,² Natasha Kyprianou,²
and Ramachandra S. Hosmane^{1,*}**

¹Laboratory for Drug Design and Synthesis, Department of Chemistry
& Biochemistry, University of Maryland, Baltimore County,
1000 Hilltop Circle, Baltimore, Maryland


²Department of Surgery, University of Maryland School of Medicine,
Baltimore, Maryland

ABSTRACT

The ring-expanded ("fat") nucleoside, 4,8-diamino-6-imino-6*H*-1- β -D-ribofuranosylimidazo[4,5-*e*][1,3]diazepine (**1**) and its 2',3',5'-tri-*O*-benzoyl derivative (**2**) exhibited potent broad spectrum anticancer activities *in vitro* against a wide variety of human tumor cell lines. The tribenzoyl derivative **2** was found to be considerably more active than the parent nucleoside **1**. Further studies using human prostate cancer cells PC-3 and DU-145 suggest that the treatment of exponentially growing culture cells with **1** and **2** leads to marked loss of cell viability in a dose-dependent manner.

Ring-expanded ("Fat") purine nucleosides and nucleotides are of chemical, biochemical, biophysical and medicinal interest (1–3). A number of such nucleoside analogues were recently discovered to possess potent *in vitro* anticancer activities against a wide variety of human tumor cell lines. In particular, we report here the broad spectrum anticancer activities of our two leading "fat" nucleosides,

*Corresponding author.



4,8-diamino-6-imino-6*H*-1- β -D-ribofuranosylimidazo[4,5-*e*][1,3]diazepine (**1**) and its 2',3',5'-tri-*O*-benzoyl derivative (**2**). While the activity profiles for the two nucleosides were similar, the latter was considerably more active than the parent nucleoside **1** in almost all the human tumor cell lines screened. The benzoyl protecting groups are believed to enhance the cell permeability of **2**.

Nucleosides **1** and **2** were synthesized using the procedure that we reported previously (4). 4,5-Dicyanoimidazole was condensed with guanidine to prepare the required heterocyclic base. The latter was ribosylated with 1-*O*-acetyl-2,3,5-tri-*O*-benzoyl- β -D-ribofuranose by the Vorbrüggen method (5), employing *N*, *O*-bis(trimethylsilyl)trifluoroacetamide (BSTFA) (for silylation) and trimethylsilyl trifluoromethanesulfonate (TMS-triflate) (as a catalyst for condensation), to obtain the tribenzoyl derivative **2**. The latter, upon treatment with a solution of sodium methoxide in methanol afforded **1**.

Nucleosides **1** and **2** were screened (6) for antitumor activity against 54 different human tumor cell lines *in vitro*. The assay was conducted according to the published procedure (7). Briefly, cell suspensions were diluted according to the particular cell type and the expected target cell density (5000–40,000 cells per well based on cell growth characteristics), and were added by pipette (100 μ L) into 96-well microtiter plates. Inoculates were allowed a preincubation period of 24 hours at 37°C for stabilization. Dilutions at twice the intended test concentrations of compounds were added at time zero in 100 μ L aliquots to the microliter plate wells. The plates were incubated for 48 hours in 5% CO₂ atmosphere and 100% humidity. The cells were assayed by using the sulforhodamine B assay (8). The plates were read by plate reader. The GI₅₀, TGI, and LC₅₀ were calculated from the optical densities. The test results showed potent anticancer activities for **1** and **2** against a wide variety of human tumor cell lines grouped under leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, and breast cancer with GI₅₀ values ranging between 10⁻⁵–10⁻⁶ *M* for **1** and 10⁻⁵–10⁻⁷ *M* for **2**.

In light of the broad spectrum *in vitro* anticancer activities of **1** and **2**, we decided to focus our further efforts on prostate cancer using our most active nucleoside **2**. Prostate cancer is the second leading cause of cancer mortality in American males (9). Our initial goal was to explore the *in vitro* effect of **2** in two androgen-independent human prostate cancer cell lines, PC-3 and DU-145, in which



the NCI screening data (6). had already exhibited marked anticancer activities. The *in vitro* effect studies concentrated on exploring the dose-dependent induction of apoptosis (programmed cell death) in treated cancer cells.

We investigated the dose response profile of the cytotoxic effects of nucleoside **2** against human prostate cancer cells. Specifically, PC-3 and DU-145 cells were each treated with increasing concentrations of **1** or **2** (0–50 μ M) for 2 days, and the cell viability was determined using the trypan blue exclusion assay (10). The results in each case indicated that the treatment of exponentially growing culture of cells with **1** or **2** for 2 days leads to marked loss of cell viability in a dose-dependent manner.

We then investigated the time course of cytotoxicity of **1** and **2** against androgen-independent prostate cancer cells. After 6 days of treatment of PC-3 and DU-145 cells each with 30 μ M concentrations of **1** or **2**, $\geq 98\%$ cell killing was observed.

In conclusion, ring-expanded nucleosides bearing the skeletal structure of **1** hold good promise as potential chemotherapeutic agents against cancer, including but not limited to, human prostate cancer.

ACKNOWLEDGMENT

This research was supported by a research grant (#1RO1 CA71079) from the National Cancer Institute of the National Institutes of Health.

REFERENCES

1. Bretner, M.; Beckett, D.; Sood, R.; Hosmane, R. S. *Bioorg. Med. Chem.* **1999**, *7*, 2931–2936.
2. Rajappan, V. P.; Hosmane, R. S. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 3649–3652.
3. Hosmane, R. S.; Hong, M. *Biochem. Biophys. Res. Commun.* **1997**, *236*, 88–93.
4. Wang, L.; Bhan, A.; Hosmane, R. S. *Nucleosides Nucleotides* **1994**, *13*, 2307–2320.
5. (a) Vorbrüggen, H.; Bennua, B. *Chem. Ber.* **1981**, *114*, 1279–1286. (b) Vorbrüggen, H.; Krolikiewicz, K.; Bennua, B. *Chem. Ber.* **1981**, *114*, 1234–1255.
6. *In Vitro* screening was performed by the National Cancer Institute (NCI) under the auspices of the NCI's Developmental Therapeutics program.
7. Monks, A. *et al.*, *J. Natl. Cancer Inst.* **1991**, *83*, 757–766.
8. Rubinstein, L. V. *et al.*, *J. Natl. Cancer Inst.* **1990**, *82*, 1107–1112.
9. Wingo, P. A.; Tong, T. N.; Bolden, S.; Wingo, P. A. *Ca Cancer J. Clin.* **1997**, *47*, 5–27.
10. (a) Fuse, T.; Yoon, K. W.; Kato, T.; Yamada, K. *Neurosurgery* **1998**, *42*, 843–849. (b) Gao, Z. H.; Briggs, W. A.; Rose, N. R.; Burdick, J. F. *J. Immunoassay*, **1998**, *19*, 129–143.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002487>